BRPI0519684A2 - formulaÇço complexa de inibidor de reductase 3 hidràxi-metil glutaril coa e agente anti-hipertensço, e processo para preparaÇço da mesma - Google Patents

formulaÇço complexa de inibidor de reductase 3 hidràxi-metil glutaril coa e agente anti-hipertensço, e processo para preparaÇço da mesma

Info

Publication number
BRPI0519684A2
BRPI0519684A2 BRPI0519684-1A BRPI0519684A BRPI0519684A2 BR PI0519684 A2 BRPI0519684 A2 BR PI0519684A2 BR PI0519684 A BRPI0519684 A BR PI0519684A BR PI0519684 A2 BRPI0519684 A2 BR PI0519684A2
Authority
BR
Brazil
Prior art keywords
complex formulation
antihypertensive agent
formulation
reductase
inhibitor
Prior art date
Application number
BRPI0519684-1A
Other languages
English (en)
Inventor
Young Ii Kim
Moon Hyuk Chi
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BRPI0519684A2 publication Critical patent/BRPI0519684A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULAÇçO COMPLEXA DE INIBIDOR DE REDUCTASE 3-HIDRàXI-3-METIL GLUTARIL COA E AGENTE ANTI-HIPERTENSçO, E PROCESSO PARA PREPARAÇçO DA MESMA. Uma formulação complexa para administração oral compreendendo uma formulação de liberação controlada de um inibidor de reductase HMG-CoA e uma camada de filme para liberação rápida de um agente anti-hipertensão, a camada de filme sendo revestida na formulação de liberação controlada, pode obter efeitos terapêuticos aperfeiçoados do agente anti-hipertensão pela liberação imediata do mesmo, enquanto mantém um nível constante de droga do inibidor de HMG-CoA redutase em sangue através de uma liberação lenta. Por conseguinte, a formulação complexa é útil para evitar e tratar doenças como hiperlipidemia, aterosclerose, hipertensão e doença cardiovascular.
BRPI0519684-1A 2004-12-30 2005-12-28 formulaÇço complexa de inibidor de reductase 3 hidràxi-metil glutaril coa e agente anti-hipertensço, e processo para preparaÇço da mesma BRPI0519684A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040116328A KR100582347B1 (ko) 2004-12-30 2004-12-30 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
PCT/KR2005/004607 WO2006071077A1 (en) 2004-12-30 2005-12-28 Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same

Publications (1)

Publication Number Publication Date
BRPI0519684A2 true BRPI0519684A2 (pt) 2009-03-03

Family

ID=36615156

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519684-1A BRPI0519684A2 (pt) 2004-12-30 2005-12-28 formulaÇço complexa de inibidor de reductase 3 hidràxi-metil glutaril coa e agente anti-hipertensço, e processo para preparaÇço da mesma

Country Status (12)

Country Link
US (1) US20080096866A1 (pt)
EP (1) EP1835903A4 (pt)
JP (1) JP2008526732A (pt)
KR (1) KR100582347B1 (pt)
CN (1) CN101090718B (pt)
AU (1) AU2005320361B2 (pt)
BR (1) BRPI0519684A2 (pt)
CA (1) CA2592287A1 (pt)
IL (1) IL183920A0 (pt)
MX (1) MX2007007843A (pt)
RU (1) RU2381798C2 (pt)
WO (1) WO2006071077A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100795419B1 (ko) * 2006-01-03 2008-01-17 (주)네오메딕스 암로디핀 및 아스피린을 함유하는 약학 제제
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US8642083B2 (en) 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
US8394845B2 (en) 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
US20110212175A1 (en) * 2006-10-30 2011-09-01 Hanall Biopharma Co., Ltd. Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
WO2009127922A2 (ko) * 2008-02-22 2009-10-22 한올제약 주식회사 심혈관계 질환 치료용 약제학적 제제
WO2009120052A1 (es) * 2008-03-24 2009-10-01 Laboratorios Pisa, S.A. De C.V. Composición farmacéutica con efecto sinérgico para el tratamiento de hipertensión arterial y dislipidemia
US20110123612A1 (en) * 2008-04-10 2011-05-26 Sung Wuk Kim Pharmaceutical preparation containing non-dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker
CN101990428A (zh) * 2008-04-10 2011-03-23 韩兀生物制药株式会社 药物制剂
JP5558023B2 (ja) * 2008-04-18 2014-07-23 第一三共株式会社 医薬品組成物
US20110117194A1 (en) * 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
KR20090114320A (ko) * 2008-04-29 2009-11-03 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
WO2009142421A2 (ko) * 2008-05-17 2009-11-26 한올제약주식회사 약제학적 제제
WO2010008203A2 (ko) * 2008-07-15 2010-01-21 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
WO2010008244A2 (ko) * 2008-07-18 2010-01-21 한올제약주식회사 약제학적 제제
WO2010021473A2 (ko) * 2008-08-19 2010-02-25 한올제약주식회사 약제학적 제제
JP5658172B2 (ja) * 2009-01-23 2015-01-21 ハンミ・サイエンス・カンパニー・リミテッド アムロジピン及びロサルタンを含む固形薬剤学的組成物及びその製造方法
CN101874802B (zh) * 2009-04-30 2014-02-05 成都自豪药业有限公司 一种治疗高血压和高胆固醇的缓释药物组合物
JP5442116B2 (ja) * 2009-06-25 2014-03-12 ジン ヤン ファーム カンパニー リミテッド ロサルタンカルボン酸を含有する薬学組成物及びその製造方法
WO2011060036A1 (en) * 2009-11-16 2011-05-19 Schering Corporation Bicyclic compounds and methods of use thereof
CN102370625A (zh) * 2010-08-20 2012-03-14 江苏联环药业股份有限公司 非洛地平片
ES2643693T3 (es) 2011-05-20 2017-11-23 Astrazeneca Uk Limited Composición farmacéutica de rosuvastatina cálcica
WO2013035423A1 (ja) * 2011-09-09 2013-03-14 東洋カプセル株式会社 カンデサルタンシレキセチル含有医薬組成物
WO2014142521A1 (ko) * 2013-03-12 2014-09-18 주식회사 엘지생명과학 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
CN108156807A (zh) * 2015-06-30 2018-06-12 韩美药品株式会社 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
DK4101454T3 (da) 2017-01-25 2024-06-17 The George Inst For Global Health Sammensætninger til behandling af hypertension
KR102424424B1 (ko) * 2017-03-28 2022-07-22 삼성전자주식회사 전자 장치
CN107595796A (zh) * 2017-08-31 2018-01-19 武汉中钰钰民医药科技有限公司 卡托普利或其盐的药物组合物及其制备方法
CN109758428A (zh) * 2017-11-09 2019-05-17 郑州泰丰制药有限公司 一种含有卡托普利的速缓释制剂及其制备方法
KR20210038931A (ko) * 2018-07-26 2021-04-08 더 조지 인스티튜트 포 글로벌 헬스 고혈압 치료용 조성물
WO2022247952A1 (zh) * 2021-05-28 2022-12-01 上海博志研新药物技术有限公司 硝苯地平美托洛尔缓释组合物、其制备方法及应用
JP7561726B2 (ja) * 2021-11-17 2024-10-04 グンゼ株式会社 樹脂成形体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
JP3883205B2 (ja) 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
CN1183044A (zh) * 1995-04-03 1998-05-27 中外制药株式会社 含有硫糖铝的制剂组合物
TR200000562T2 (tr) * 1997-08-29 2000-08-21 Pfizer Products Inc. Amlodifin ve bir statin bileşiği içeren bileşim terapisi
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
EE200000186A (et) * 1997-11-03 2001-04-16 Janssen Pharmaceutica N.V. Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US20030092745A1 (en) * 2000-02-25 2003-05-15 Pfizer Inc. Combination therapy
CA2405793A1 (en) * 2000-04-12 2001-10-18 Novartis Ag Combination of organic compounds
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US20020077348A1 (en) * 2000-11-21 2002-06-20 Dean Herbert M. Dosage unit for cardioprotection
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition

Also Published As

Publication number Publication date
IL183920A0 (en) 2007-10-31
AU2005320361A1 (en) 2006-07-06
JP2008526732A (ja) 2008-07-24
CA2592287A1 (en) 2006-07-06
EP1835903A4 (en) 2009-12-30
CN101090718A (zh) 2007-12-19
WO2006071077A1 (en) 2006-07-06
RU2007128948A (ru) 2009-02-10
MX2007007843A (es) 2007-08-17
EP1835903A1 (en) 2007-09-26
CN101090718B (zh) 2010-11-10
KR100582347B1 (ko) 2006-05-22
US20080096866A1 (en) 2008-04-24
RU2381798C2 (ru) 2010-02-20
AU2005320361B2 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
MX2007007843A (es) Formulacion de complejo de inhibidor de 3-hidroxi-3-metil glutaril coa reductasa y agente antihipertensivo, y proceso para su preparacion.
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
BR0315580A (pt) Derivados de metileno uréia
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
NO331021B1 (no) Medikament for behandling av kreft omfattende kinolonderivater i kombinasjon med 5-FU eller CPT-11 samt anvendelse av derivatene
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
UA92920C2 (ru) Таблетка с насечкой, включающая питавастатин, и имеющая превосходную фотостабильность
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
WO2002007721A3 (en) Use of cox-2 inhibitors for preventing immunodeficiency
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
BRPI0509194A (pt) formulação e método de comprimido revestido
BRPI0509710A8 (pt) Formulação de liberação controlada para administração oral de inibidor de hmg-coa redutase e método para preparação da mesma
BRPI0616834A2 (pt) composto e os sais e ésteres farmaceuticamente aceitáveis do mesmo, métodos para reduzir os níveis de colesterol-ldl do plasma, para tratar hipercolesterolemia, método para tratar ou reduzir o risco de desenvolver aterosclerose e para reduzir o risco de ter um evento de doença aterosclerótica, e, composição farmacêutica
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
DOP2010000197A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.